Document ID: chunk:federal_register_of_legislation:F2024L00483:reg:9:p1
Version: federal_register_of_legislation:F2024L00483
Segment Type: reg
Provision Reference: reg 9 (pt 1/2)
Character Range: 4420–8611

9               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting myasthenia gravis or death from myasthenia gravis with the circumstances of a person's relevant service:
(1)          being treated with one of the following medications within the 3 months before clinical onset:
(a)          alemtuzumab;
(b)          Bacille Calmette-Guerin;
(c)          carbamazepine;
(d)          chloroquine;
(e)          dabrafenib;
(f)           etanercept;
(g)          gabapentin;
(h)          HMG coenzyme A reductase inhibitors (statins);
(i)            hydroxychloroquine;
(j)            imatinib;
(k)          immune checkpoint inhibitors including ipilimumab, nivolumab, pembrolizumab, atexolizumab, avelumab, dostarlimab, and durvalumab;
(l)            interferon alpha;
(m)        lithium carbonate;
(n)          lorlatinib;
(o)          nilotinib;
(p)          omalizumab;
(q)          penicillamine;
(r)           phenytoin;
(s)           trametinib;
(t)            trimethadione;
(2)          being treated with one of the following medications at the time of the clinical worsening:
(a)          acetazolamide;
(b)          alemtuzumab
(c)          amantadine;
(d)          amitriptyline;
(e)          anaesthetic agents;
(f)           antibiotics;
(g)          Bacille Calmette-Guerin;
(h)          beta-blockers;
(i)            botulinum toxin;
(j)            calcium channel blockers;
(k)          carbamazepine;
(l)            chloroquine;
(m)        chlorpromazine;
(n)          cocaine;
(o)          colchicine;
(p)          dabrafenib;
(q)          diphenhydramine;
(r)           droperidol;
(s)           echothiophate;
(t)            ementine;
(u)          ergometrine;
(v)          etafenone;
(w)        etanercept
(x)          ethosuximide;
(y)          gabapentin;
(z)          haloperidol;
(aa)       HMG coenzyme A reductase inhibitors (statins);
(bb)      hydroxychloroquine;
(cc)       imatinib;
(dd)      imipramine;
(ee)       immune checkpoint inhibitors;
(ff)        interferon alpha;
(gg)      interleukin-2;
(hh)      levonorgestrel implant;
(ii)         lithium carbonate;
(jj)         lorlatinib;
(kk)      magnesium sulphate;
(ll)         mefloquine;
(mm) nicotine transdermal patch;
(nn)      nilotinib;
(oo)      omalizumab;
(pp)      paraldehyde;
(qq)      potassium losing diuretics;
(rr)        penicillamine;
(ss)        peruvoside;
(tt)         phenytoin;
(uu)      procainamide;
(vv)      proguanil;
(ww)  propafenone;
(xx)      pyrantel pamoate;
(yy)      quinidine;
(zz)       quinine;
(aaa)   ribavirin;
(bbb)  sedative analgesics including barbiturates, muscle relaxants, narcotics and tranquillisers;
(ccc)   systemic corticosteroids;
(ddd)  thyroid hormone replacement therapy;
(eee)   tiopronin;
(fff)      trametinib;
(ggg)  trientine;
(hhh)  trihexyphenidyl;
(iii)       trimethadione;
(jjj)       trimethaphan;
(3)          having an injection of an iodinated radiological contrast agent within the 24 hours before clinical worsening;
Note: Iodinated contrast agents include but are not limited to iothalamic acid, diatrizoate meglumine and diatrizoate sodium.
(4)          undergoing haematopoietic stem cell transplantation before clinical onset or clinical worsening;
(5)          being pregnant within the 6 weeks before clinical worsening;
(6)          having an infection with any of the following conditions in the 2 months before clinical worsening:
(a)          pneumonia;
(b)          influenza;
(c)          severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection;
(d)          upper respiratory tract infection;
(e)          urinary tract infection;
(f)           gastrointestinal infection;
(g)          septicaemia;
(7)          having major surgery or major trauma within the 2 months before clinical worsening;
(8)          receiving the ChAdOx1 nCoV-19 vaccine within the 2 months before the clinical onset or clinical worsening;
(9)          experiencing a category 1A stressor within the 30 days before clinical worsening;
Note: category 1A stressor is defined in the Schedule 1 – Dictionary.
(10)